Correlation of CCL8 expression with immune cell infiltration of skin cutaneous melanoma: potential as a prognostic indicator and therapeutic pathway

Peipei Yang¹, Wanrong Chen², Hua Xu³, Junhan Yang¹, Jinghang Jiang²,4, Yunhui Jiang³* and Ganglin Xu¹* (Correspondence: jmyunhuijiang@163.com; jmganglinxu@163.com)

Abstract

Background: The tumor microenvironment (TME) is critical in the progression and metastasis of skin cutaneous melanoma (SKCM). Differences in tumor-infiltrating immune cells (TICs) and their gene expression have been linked to cancer prognosis. Given that immunotherapy can be effective against SKCM, we aimed to identify key genes that regulate the immunological state of the TME in SKCM.

Methods: Data from 471 SKCM patients in the The Cancer Genome Atlas were analyzed using ESTIMATE algorithms to generate an ImmuneScore, StromalScore, and EstimateScore for each patient. Patients were classified into low- or high-score groups based on median values, then compared in order to identify differentially expressed genes (DEGs). Then a protein–protein interaction (PPI) network was developed, and a prognostic model was created using uni- and multivariate Cox regression as well as the least absolute shrinkage and selection operator (LASSO). Key DEGs were identified using the web-based tool GEPIA. Profiles of TIC subpopulations in each patient were analyzed using CIBERSORT, and possible correlations between key DEG expression and TICs were explored. Levels of CCL8 were determined in SKCM and normal skin tissue using immunohistochemistry.

Results: Two scores correlated positively with the prognosis of SKCM patients. Comparison of the low- and high-score groups revealed 1684 up-regulated and 18 down-regulated DEGs, all of which were enriched in immune-related functions. The prognostic model identified CCL8 as a key gene, which CIBERSORT found to correlate with M1 macrophages. Immunohistochemistry revealed strong expression in SKCM tissue, but failed to detect the protein in normal skin tissue.

Conclusions: CCL8 is a potential prognostic marker for SKCM, and it may become an effective target for melanoma in which M1 macrophages play an important role.

Keywords: Tumor microenvironment, Tumor-infiltrating immune cells, Skin cutaneous melanoma, M1 macrophages

Background

Skin cutaneous melanoma (SKCM) is a common potentially malignant condition, and its prevalence has increased more than sixfold in the last six decades [1]. In 2020, more than 324,000 new SKCM cases and 57,000 deaths occurred, representing about one in 19 cancer cases and 23 cancer deaths [2, 3]. The annual...
incidence of SKCM will likely remain high as populations increase.

The distribution of melanoma subtypes varies with geography and ethnicity: in China, acral and mucosal SKCM are the most frequent subtypes of melanoma [4, 5]. Surgical resection is the standard treatment for early-stage SKCM, when it is often curative [6]. Systemic therapy is the standard for advanced SKCM, which is associated with poor prognosis [7, 8].

SKCM is associated with abnormal regulation of tumor-related genes [7, 9–11], including genes related to immune responses [12]. Extracellular matrix growth factors, secreted metabolites, and dynamic interactions among endothelial, interstitial, and immune cells create a tumor microenvironment (TME) that strongly affects tumor proliferation, differentiation, migration, and invasion [13–15]. In this way, mesenchymal cells, tumor-infiltrating immune cells (TICs), and fibroblasts regulate tumor progression [16–20], while tumor-associated macrophages infiltrate the TME, stimulating SKCM angiogenesis, growth and invasion [21, 22]. Thus, immunotherapy is increasingly being used in cancer treatment [7, 9, 10, 23, 24], but it can be rendered ineffective because of the TME and tumor heterogeneity. In this way, TICs in the TME are a key determinant of the therapeutic response.

Therefore, it is important to identify biomarkers that may facilitate early identification of SKCM or help predict response to treatment. Toward that end, we used the ESTIMATE algorithm to characterize the TME, and we established a prognostic model using Cox regression and the Least Absolute Shrinkage and Selection (LASSO). The model identified four differentially expressed genes (DEGs), one of which, CCL8, was identified as key by the web-based tool GEPIA. Expression of this gene was found to correlate with tumor infiltration by M1 macrophages using the CIBERSORT algorithm.

**Materials and methods**

**Samples**

Transcriptome data for SKCM tissues and adjacent non-cancerous tissues from 471 patients were extracted from The Cancer Genome Atlas (https://portal.gdc.cancer.gov/), together with the patients’ clinical information. Tissues were also obtained from SKCM patients at our institution.

This study was approved by the Ethics Committee of Jingmen No. 2 People’s Hospital, and procedures involving humans and their samples were performed in accordance with the Declaration of Helsinki.

**Calculation of immune and stromal scores using the ESTIMATE algorithm**

We used the “ESTIMATE” algorithm in R (https://www.r-project.org/) to determine an EstimateScore, ImmuneScore, and StromalScore for the TME of SKCM tissue based on transcriptomic data. For each score, patients were assigned to low- or high-score groups according to the median value for that score. Survival of the two groups was compared using the “survminer” package in R, and potential correlations between scores and clinical characteristics were explored.

**DEGs and their functional analysis**

Within each of the three scores, we compared the low- and high-score groups using the “limma” package in R in order to identify DEGs between them. DEGs with a |log<sub>2</sub>(fold change)| > 1 and false discovery rate < 0.05 were considered significant and retained in the analysis. Heatmaps of DEGs were created using the “pheatmap” package in R.

Potential functions of DEGs were identified by examining them for enrichment in Gene Ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. Enrichment was considered significant if P < 0.05 and q < 0.05.

**Protein–protein interaction (PPI) network**

PPI networks of DEGs were constructed using the STRING website (string-db.org) at a confidence level of 0.9. The 30 genes with the largest numbers of interconnected nodes were visualized using the “cytoHubba” plug-in in Cytoscape software.

**Prognostic model**

A total of 454 SKCM patients in The Cancer Genome Atlas, for whom complete survival data were available, were randomly divided 1:1 between a training group and a validation group. In the training group, patients were divided into low- and high-score groups based on median risk score, and their Kaplan–Meier survival curves were compared. Univariate Cox regression was used to identify immune-related genes that were significantly related to overall survival of SKCM patients based on the corresponding hazard ratio. A de novo prognostic model was created using LASSO and the “glmnet” package in R, then the genes in the model were refined using multivariate Cox regression.

The final prognostic model was validated by calculating a consistency index, calibration chart, and areas under the receiver operating characteristic curve (AUCs).

In addition, we validated the differential expression of model genes between normal and tumor tissues using
GEPIA (http://gepia.cancer-pku.cn/), and we examined potential correlations between the key genes obtained and patients’ clinical features.

These analyses involved the following packages in R: “rms”, “foreign”, “survival”, “survivalROC”, and “stdca.R”. Results were considered significant if associated with \( P < 0.05 \).

Analysis of TICs

The CIBERSORT algorithm was used to determine relative proportions of 22 types of immune cells in the SKCM patients from The Cancer Genome Atlas. After filtering out data that did not meet the significance criterion of \( P < 0.05 \), 228 patients were retained in the final analysis.

Based on median levels of immune cell content, we stratified patients into low- or high-level groups and compared their survival using the Kaplan–Meier method in order to identify immune cell types associated with survival. We also explored the correlation between key genes and the 22 types of immune cells.

Immunohistochemistry of CCL8

SKCM and normal tissues were collected from surgical samples of patients treated at Jingmen No. 2 People’s Hospital. The tissue was paraffin-embedded and the paraffin blocks were cut into 4-μm sections, dewaxed in xylene, and hydrated through a graded series of ethanol solutions (100, 90, 80, and 70%). The sections were incubated in 1× ethylenediaminetetraacetic acid antigen repair solution for 20 min at room temperature, then washed three times with tap water. Endogenous peroxidases were blocked by soaking sections in 3% \( \text{H}_2\text{O}_2 \) for 10–30 min.

Sections were stained with primary rabbit antibody against CCL8 (catalog no. NBP1-79937, NOVUS Biologicals, USA) at a dilution of 1:100 at 4 °C. The sections were washed three times with phosphate-buffered saline (PBS) for 5 min, incubated with anti-rabbit secondary antibody at room temperature for 10 min, rinsed again in PBS, and incubated with anti-horseradish peroxidase conjugate for 10 min. Finally, sections were counterstained with hematoxylin for 1–3 min, rinsed three times with PBS, and incubated in 1% hydrochloric acid-alcohol. Two expert pathologists independently analyzed the sections.

Results

Correlations between scores and survival of SKCM patients

Kaplan–Meier analysis was used to explore correlations of the EstimateScore, ImmuneScore and StromalScore with survival of SKCM patients (Fig. 1A–C). The first two scores correlated significantly with prognosis (\( P < 0.001 \)).

Correlations between scores and clinical features of SKCM patients

EstimateScores and ImmuneScores, but not StromalScores, were significantly different between patients in stage 0-I or stage II-IV (Fig. 2A–L). All three scores differed significantly between patients in stage T0-2 or T3-4. StromalScores, but not the other two scores, differed significantly between patients in stage N0 or N1-3, as well as between patients in stage M0 or M1.

DEGs between patients with low or high scores

We identified 1684 up-regulated genes and 154 down-regulated DEGs between patients with low or high ImmuneScores (Fig. 3A). We also identified 1953 up-regulated and 102 down-regulated DEGs between patients with low or high StromalScores (Fig. 3B). A total of 1684 up-regulated and 18 down-regulated genes overlapped between the two sets of DEGs (Fig. 3C, D).

Functional enrichment of DEGs

DEGs were enriched mainly in the GO terms related to immunological response, immunoreceptor components, and immunoglobulin receptor binding (Fig. 4A). DEGs were enriched mostly in the KEGG pathways related to

![Fig. 1 Correlation of A EstimateScore, B ImmuneScore and C StromalScore with overall survival of SKCM patients, based on Kaplan–Meier analysis](image-url)
synthetic and metabolic pathways (Fig. 4B). The 30 genes with the largest numbers of interconnected nodes were calculated and displayed in the PPI network (Fig. 4C).

**Hub gene identification and establishment of a prognostic model**
Significant DEGs were selected for LASSO regression after single-factor Cox regression analysis, and nine genes were filtered and screened for multi-factor Cox regression. Multi-factor Cox regression identified four genes closely related to overall survival of SKCM patients: PLA2G5, ABCB1, CCL8, and KLRK1 (Fig. 5).

**Validation of the prognostic model**
We constructed a prognostic model based on the above-mentioned four genes, as well as a nomogram for predicting overall survival at 5, 10 and 20 years (Fig. 6A, B). In the training group, Kaplan–Meier analysis showed lower survival rates among patients in the high-risk group than among patients in the low-risk group. High-risk patients showed low expression of all four genes (Fig. 6C, E). Similar results were obtained in the validation dataset and in the dataset comprising all patients (Fig. 7A–C). AUCs at 5, 10, and 20 years were as follows: training group, 0.718, 0.738, and 0.776 (Fig. 7D); validation group, 0.662, 0.699, and 0.818 (Fig. 7E); and all patients, 0.69, 0.716, and 0.795 (Fig. 7F).

Using GEPIA, we verified the survival differences between patients expressing low or high levels of the four genes, and we found significantly higher CCL8 expression in tumors (Fig. 8A–D). Stratifying patients based on median expression of CCL8 showed that those expressing high levels of the protein had significantly longer overall survival (P < 0.001; Fig. 9A). In addition, CCL8 expression differed significantly between patients in stage II–IV or stage 0–I (Fig. 9B), as well as between patients in stage T0-2 or T3-4 (Fig. 9C).

**CCL8 expression and TICs**
Among the 228 patients for which CIBERSORT analysis of TICs passed the significance threshold (Fig. 10A, B), patients showing high levels of M1 macrophages showed better survival than patients with low levels (Fig. 10C). In
Fig. 3  Differentially expressed genes (DEGs) between patients with low or high ImmuneScores or StromalScores. A, B Heat map of the top 50 up- and down-regulated DEGs between patients with low or high scores. C, D Venn plot showing the DEGs common to the comparisons based on ImmuneScore or StromalScore.

Fig. 4  Functional Enrichment of DEGs. A Enrichment in Gene Ontology (GO) terms. B Enrichment in Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. C Protein–protein interaction (PPI) network for the 30 genes with the largest numbers of interconnected nodes.
addition, CCL8 expression correlated positively with M1 macrophages (Fig. 10D).

**Immunohistochemistry of CCL8**

To verify our in silico analyses, we investigated CCL8 expression in SKCM and normal skin tissues. SKCM tissue showed abundant cytoplasmic CCL8 expression (Fig. 11A), whereas the protein was undetectable in adjacent normal tissue (Fig. 11B, C). Clinical features of the patients are shown in Table 1.

**Discussion**

Only 5% of all cases of skin cancer are SKCM and its global incidence is estimated to be 15–25 per 100,000 individuals, yet it accounts for 80% of fatal cases of skin cancer [25, 26]. If metastasis occurs, SKCM can lead to intractable metastatic melanoma. The present study focused on TICs in the disease because researchers have increasingly been exploring possibilities of immunotherapy against SKCM [27, 28] and have achieved important successes [29, 30]. Immune cells in the TME interact with tumor cells and other cell types to strongly influence cancer progression [31]. Therefore, finding tumor biomarkers that may be linked to the SKCM and prognosis is essential.

Our analysis of immune and stromal components in the TME of SKCM using the ESTIMATE algorithm identified four putative prognostic biomarkers, one of which we verified experimentally: CCL8. Also known as monocyte chemotactic protein-2CC, CCL8 is one of the smallest chemokines and it triggers chemotactic activity in monocytes, lymphocytes, basophils, and eosinophils [26, 32]. Previous work has indicated an oncogenic role for CCL8: its expression correlates positively with progression of various cancers [33, 34], including breast cancer [35, 36], and with metastasis of cancers to the lung [37]. Conversely, the present study suggests that, at least in melanoma, CCL8 can play a protective role: high levels of CCL8 correlated with better prognosis. Our findings are consistent with a report that combining CCL8 with CCR5 can treat rectal cancer [38].

CIBERSORT analysis of SKCM patients in our study showed that a higher proportion of M1 macrophages among TICs was associated with better survival. M1 macrophages, also known as classically activated macrophages, secrete pro-inflammatory factors to support immune responses. In fact, M1 macrophages can be exploited to deliver antitumor drugs [39–41], and therapy that simultaneously upregulates M1 macrophages and downregulates M2 macrophages can be effective against cancers [42]. Our study found a positive correlation between CCL8 expression and levels of M1 macrophages, suggesting that CCL8 may help drive the anti-tumor efficacy of M1 macrophages in the TME. Indeed, one
Fig. 6 (See legend on previous page.)
study found that CCL8 sensitized mice with cutaneous squamous cell carcinoma to photodynamic therapy by recruiting M1 macrophages [43]. In this way, our analyses suggest that CCL8 may influence immune activity in the TME, such as by promoting antitumor responses of M1 macrophages. This may help explain why CCL8 expression correlates with overall survival of SKCM patients.

**Fig. 7** The four-gene signature risk score was determined based on Kaplan–Meier analysis of overall survival and on receiver operating characteristic curves. **A–C** Analysis of the training group, validation group and all patients in the study. **D–F** Time-dependent receiver operating characteristic curves for 5, 10 and 20 years in the training group, validation group, and all patients in the study.

**Fig. 8** Verification of survival differences based on GEPIA. **A–D** Differences in the expression of CCL8, ABCB1, KLRK1, and PLA2G5 between tumor and normal tissues. The difference in CCL8 expression was statistically significant.
Fig. 9  The prognostic role of CCL8 in SKCM. A Relationship between CCL8 expression and SKCM prognosis. B, C Correlation between CCL8 expression and clinical features.

Fig. 10  Analysis of TICs and CCL8. A Relative proportions of 22 immune cell types in each patient, based on the CIBERSORT algorithm. B Correlations among the 22 immune cell types. Blue and red represent positive and negative relationships, respectively. C Correlation between M1 macrophages and patient survival. D Positive correlation between CCL8 expression and M1 macrophages.
Conclusion
Based on bioinformatics analysis of The Cancer Genome Atlas, our study identifies CCL8 as a potential prognostic marker in SKCM and as part of a therapeutic pathway involving M1 macrophages that may be exploited to improve treatment options for patients.

Acknowledgements
The authors thank Armando Chapin Rodriguez, PhD, for language editing and the authors who uploaded the data to TCGA project.

Authors’ contributions
GX, YJ and PY designed the study. PY, WC, and HX performed the data collection. HX and YJ performed the Immunohistochemical analysis. WC, JY and JJ evaluated the data and performed the statistical analysis. PY wrote the manuscript.

Funding
General Science and Technology Planning Project of Jingmen (2020YFYB009).

Availability of data and materials
The public datasets used in our work can be found on https://portal.gdc.cancer.gov/ and http://gepia.cancer-pku.cn/. Immunohistochemical datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
This study was approved by the Jingmen No.2 People’s hospital ethics committee and was conducted in line with the Declaration of Helsinki.

Table 1  Clinical features of the six SKCM patients whose tissues were analyzed by immunohistochemistry

| Patient no. | Sex | Age, year | Tumor size, cm |
|-------------|-----|-----------|---------------|
| 1           | Female | 42   | 2.1 × 1.4 × 0.7 |
| 2           | Male   | 38   | 1.9 × 1.3 × 0.5 |
| 3           | Male   | 57   | 3.2 × 1.9 × 0.8 |
| 4           | Female | 63   | 1.5 × 1.0 × 1.0 |
| 5           | Male   | 38   | 2.8 × 2.1 × 1.3 |
| 6           | Female | 50   | 2.7 × 1.6 × 0.5 |

References
1. Welch HG, Mazer BL, Adamson AS. The rapid rise in cutaneous melanoma diagnoses. N Engl J Med. 2021;384(1):72–9.
2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
3. Singh A, Fatima K, Srivastava A, Khwaja S, Priya D, Singh A, et al. Anticancer activity of gallic acid template-based benzylidene indanone derivative as microtubule destabilizer. Chem Biol Drug Des. 2016;88(5):625–34.
4. Guo J, Qin S, Liang J, Lin T, Lu S, Chen X, et al. Chinese guidelines on the diagnosis and treatment of melanoma (2015 Edition). Chin Clin Oncol. 2016;5(4):57.
5. Sathish Kumar B, Kumar A, Singh J, Hasanain M, Singh A, Fatima K, et al. Synthesis of 2-alkoxy and 2-benzyloxy analogues of estradiol as anti-breast cancer agents through microtubule stabilization. Eur J Med Chem. 2014;86:740–51.
6. Kalaora S, Lee JS, Barnea E, Levy R, Greenberg P, Alon M, et al. Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma. Nat Commun. 2020;11(1):896.
7. Akbani R, Akdemir KC, Aksoy BA, Albert M, Alty A, Amin SB, et al. Genomic classification of cutaneous melanoma. Cell. 2015;161(7):1681–96.
8. Sathish Kumar B, Singh A, Kumar A, Singh J, Hasanain M, Singh A, et al. Synthesis of 2-alkoxy and 2-benzyloxy analogues of estradiol as anti-breast cancer agents through microtubule stabilization. Eur J Med Chem. 2014;86:740–51.
9. Schadendorf D, van Akkooi ACJ, Berking C, Griewank KG, Gutzmer R, Hauschild A, et al. Melanoma. Lancet. 2018;392(10151):971–84.
10. Rambow F, Marine J, Goding CR. Melanoma plasticity and phenotypic diversity: therapeutic barriers and opportunities. Gene Dev. 2019;33(19–20):1295–318.
11. Hamid AA, Kaushal T, Ashraf R, Singh A, Chand Gupta A, Prakash O, et al. (22β,25R)-3β-Hydroxy-spirost-5-en-7-mono-heptanodic acid.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Dermatology, Jingmen No. 2 People’s Hospital, No. 39 Xiangshan Road Dongbao Zone, Jingmen 448000, Hubei, China. 2 Graduate School, Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China. 3 Department of Pathology, Jingmen No. 2 People’s Hospital, No. 39 Xiangshan Road Dongbao Zone, Jingmen 448000, Hubei, China. 4 The Reproductive Medicine Center, Jingmen No. 2 People’s Hospital, Jingmen, Hubei, China.

Received: 29 July 2021  Accepted: 17 November 2021
Published online: 29 November 2021
exhibits anti-prostate cancer activity through caspase pathway. Steroids. 2017;119:43–52.

12. Thomas NE, Busam KJ, From L, Kricker A, Armstrong BK, Anton-Culver H, et al. Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study. J Clin Oncol. 2013;31(13):4252–9.

13. Allard B, Aspeslagh S, Garaud S, Dupont FA, Solinas C, Kock M, et al. Immuno-oncology-101: overview of major concepts and translational perspectives. Semin Cancer Biol. 2018;52(Pt2):1–11.

14. Muenst S, Lübßeli H, Soysal SD, Zipfelus A, Tankaov A, Hoeller S. The immune system and cancer evasion strategies: therapeutic concepts. J Intern Med. 2016;279(6):541–62.

15. Khwaja S, Fatima K, Hasanain M, Behera C, Kour A, Singh A, et al. Antiproliferative efficacy of curcumin mimics through microtubule destabilization. Eur J Med Chem. 2018;151:51–61.

16. Ersek B, Sillo P, Cakir U, Molnár V, Bencsik A, Mayer B, et al. Melanoma-associated fibroblasts impair CD8+ T cell function and modify expression of immune checkpoint regulators via increased arginase activity. Cell Mol Life Sci. 2021;78(2):661–73.

17. Kim HR, Park HJ, Son J, Lee JS, Chung KY, Cho NH, et al. Tumor microenvironment dictates regulatory T cell phenotype: Upregulated immune checkpoints reinforce suppressive function. J Immunother Cancer. 2019;7(1):339.

18. Erdag G, Schaeffer JT, Smolkin ME, Deacon DH, Shea SM, Dengel LT, et al. Immunotoxicity and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res. 2012;72(25):1070–80.

19. Srivastava A, Fatima K, Fatima E, Singh A, Singh A, Shukla A, et al. Fluorinated benzylidene indanone exhibits antiproliferative activity through modulation of microtubule dynamics and antiangiogenic activity. Eur J Pharm Sci. 2020;154:105513.

20. Hamid AA, Hasanain M, Singh A, Bhukya B, Vasudev PG, et al. Synthesis of novel anticancer agents through opening of spirocyclic ring of dioxogen. Steroids. 2018;127:108–18.

21. Louphrasitthiphol P, Goding CR. Macrophage cytoplasmic transfer in cancer. Cytometry A. 2019;111(12):1204–12.

22. Pucci F, Garris C, Lai CP, Newton A, Pfrörchke C, Englbröm C, et al. SCS macrophages suppress melanoma by restricting tumor-derived vesicle-ble cell interactions. Science. 2016;352(6282):242–6.

23. Topalian SL, Hodis FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–54.

24. Jain S, Singh A, Khare P, Chanda D, Mishra D, Shanker K, et al. Toxicity of immunomodulators and chemokines–protease interactions in cancer. Semin Cancer Biol. 2004;14(3):201–8.

25. Schadenhof D, Hauschild A. Melanoma in 2013: Melanoma—the run of success continues. Nat Rev Cl Oncol. 2014;11(2):75–6.

26. Van Damme J, Struyf S, Opdenakker G. Chemokine–protease interactions in cancer. Semin Cancer Biol. 2004;14(3):201–8.

27. Simeone E, Grimaldi AM, Festino L, V analella V, Palm A, Asciento PA. Combination treatment of patients with BRAF-mutant melanoma: a new standard of care. BioDrugs. 2017;31(1):51–61.

28. Ko JS. The immunology of melanoma. Clin Lab Med. 2017;37(3):449–71.

29. Roohan MV, van den Berg JH, Kvistborg P, Haenen JBAG. Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option. J Immunother Cancer. 2018;6(1):102.

30. Singh A, Mohanty I, Singh J, Rattan S. BDNF augments rat internal sphincter smooth muscle tone via RhoA/ROCK signaling and nonadenergic, noncholinergic relaxation via increased NO release. Am J Physiol Gastrointest Liver Physiol. 2020;318(1):G23–33.

31. Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. Cancer Res. 2019;79(18):4557–66.

32. Zhou J, Zheng S, Liu T, Liu Q, Chen Y, Tan D, et al. MCP2 activates NF-κB signaling pathway promoting the migration and invasion of ESCC cells. Cell Biol Int. 2018;42(3):365–72.

33. Chen X, Deng Y, Wang Z, Wei W, Zhou C, Zhang Y, et al. Hypoxia-induced ZEB1 promotes cervical cancer progression via CCL8-dependent tumour-associated macrophage recruitment. Cell Death Dis. 2019;10(7):508.

34. Zhang X, Chen L, Deng W, Cao M, Xiao J, Lv S, et al. CCL8 secreted by tumor-associated macrophages promotes invasion and stemness of glioblastoma cells via ERK1/2 signaling. Lan Invest. 2020;100(4):619–29.

35. Fránzén B, Alexeyenko A, Kamali Moghaddam M, Hatchesk T, Kanter L, Ramqvist T, et al. Protein profiling of fine-needle aspirates reveals subtype-associated immune signatures and involvement of chemokines in breast cancer. Mol Oncol. 2019;13(2):376–91.

36. Kim E, Nam S, Song HK, Lee S, Kim K, Lim HK, et al. CCL8 mediates crosstalk between endothelial colony forming cells and triple-negative breast cancer cells through IL-8, aggravating invasion and tumorigenicity. Oncogene. 2020;41(18):3245–59.

37. Yan C, Luo L, Urata Y, Goto S, Li T. Nicaraven reduces cancer metastasis to irradiated lungs by decreasing CCL8 and macrophage recruitment. Cancer Lett. 2018;418:204–10.

38. Wang W, Zhong Y, Zhuang Z, Xie J, Lu Y, Huang C, et al. Multiregion single-cell sequencing reveals the transcriptional landscape of the immune microenvironment of colorectal cancer. Clin Transl Med. 2021;11(1):e253.

39. Pang L, Zhu Y, Qin J, Zhao W, Wang J. Primary M1 macrophages as multifunctional carrier combined with PLGA nanoparticle delivering anti-cancer drug for efficient glioma therapy. Drug Deliv. 2018;25(1):1922–31.

40. Singh A, Singh J, Rattan S. Evidence for the presence and release of BDNF in the neuronal and non-neuronal structures of the internal anal sphincter smooth muscle tone via RhoA/ROCK signaling and nonadenosine, noncholinergic relaxation via increased NO release. Am J Physiol Gastrointest Liver Physiol. 2020;318(1):G23–33.

41. Travers M, Brown SM, Dunworth M, Holtbert CE, Wiehagen KR, Bachman KE, et al. DFMO and S-azacytidine increase M1 macrophages in the tumor microenvironment of murine ovarian cancer. Cancer Res. 2019;79(13):3445–54.

42. Sallam MA, Wyatt Shields IV C, Prakash S, Kim J, Pan DC, et al. A dual macrophage polarizer conjugate for synergistic melanoma therapy. J Control Release. 2021;335:333–44.

43. Ji J, Wang P, Zhou Q, Zhu L, Zhang H, Zhang Y, et al. CCL8 enhances sensitivity of cutaneous squamous cell carcinoma to photodynamic therapy by recruiting M1 macrophages. Photodiagnosis Photodyn Therapy. 2019;26:235–43.